CY1111857T1 - Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης - Google Patents

Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης

Info

Publication number: CY1111857T1
Authority: CY; Cyprus
Prior art keywords: trans; dimethylpiperazine; hulpo; finylindan; ylo
Prior art date: 2005-02-16

Application number

CY20111100928T

Other languages

Greek (el)

English (en)

Inventor

Benny Bang-Andersen

De Diego Heidi Lopez

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-16

Filing date

2011-09-27

Publication date

2015-11-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111857(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-27 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2015-11-04 Publication of CY1111857T1 publication Critical patent/CY1111857T1/el

Links

239000012971 dimethylpiperazine Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000002585 base Substances 0.000 abstract 1
239000012458 free base Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CY20111100928T 2005-02-16 2011-09-27 Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης CY1111857T1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65341905P	2005-02-16	2005-02-16
DKPA200500239		2005-02-16
EP06706059A EP1853576B1 (en)	2005-02-16	2006-02-14	Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine

Publications (1)

Publication Number	Publication Date
CY1111857T1 true CY1111857T1 (el)	2015-11-04

Family

ID=37908539

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY20111100928T CY1111857T1 (el)	2005-02-16	2011-09-27	Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης

Country Status (28)

Country	Link
US (2)	US7648991B2 (sr)
EP (1)	EP1853576B1 (sr)
JP (1)	JP5055135B2 (sr)
KR (1)	KR101386387B1 (sr)
CN (1)	CN101119983B (sr)
AR (1)	AR052909A1 (sr)
AT (1)	ATE515501T1 (sr)
AU (1)	AU2006215957B9 (sr)
BR (1)	BRPI0607436B8 (sr)
CA (1)	CA2597622C (sr)
CY (1)	CY1111857T1 (sr)
DK (1)	DK1853576T3 (sr)
EA (1)	EA017631B1 (sr)
ES (1)	ES2368786T3 (sr)
HR (1)	HRP20110645T1 (sr)
IL (1)	IL184551A (sr)
MX (1)	MX2007009980A (sr)
MY (1)	MY148683A (sr)
NO (1)	NO339863B1 (sr)
NZ (1)	NZ556397A (sr)
PL (1)	PL1853576T3 (sr)
PT (1)	PT1853576E (sr)
RS (1)	RS51944B (sr)
SI (1)	SI1853576T1 (sr)
TW (1)	TWI376373B (sr)
UA (1)	UA95901C2 (sr)
WO (1)	WO2006086986A1 (sr)
ZA (1)	ZA200705982B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1658277T3 (pl)	2003-08-18	2012-10-31	H Lundbeck As	Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI376373B (en)	2005-02-16	2012-11-11	Lundbeck & Co As H	Crystalline base of a pharmaceutical compound
TWI453198B (zh) *	2005-02-16	2014-09-21	Lundbeck & Co As H	製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
CN102065861B (zh) *	2008-05-07	2013-10-16	H.隆德贝克有限公司	反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
CN102170884A (zh) *	2008-10-03	2011-08-31	H.隆德贝克有限公司	口服制剂
DK2720989T3 (en)	2011-06-20	2016-11-28	H Lundbeck As	Deuterated 1-piperazino-3-phenyl-indanes used to treat schizophrenia
WO2020089147A1 (en)	2018-10-29	2020-05-07	H. Lundbeck A/S	Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en)	2018-12-03	2020-06-11	H. Lundbeck A/S	Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4031216A (en)	1974-08-12	1977-06-21	Knoll A.G. Chemische Fabriken	3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en)	1980-02-29	1986-08-06	Kefalas As	Indane derivatives
DE3139970A1 (de)	1981-10-08	1983-04-28	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en)	1987-04-01	1991-06-25	Janssen Pharmaceutica N.V.	4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en)	1989-02-08	1995-11-14	Biochem Pharma Inc.	Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
HUT67665A (en)	1991-11-05	1995-04-28	Smithkline Beckman Corp	Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them
CA2091204C (en)	1992-03-11	1997-04-08	Ronald J. Mattson	Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) *	1992-04-28	1992-04-28	Lundbeck & Co As H	1-piperazino-1,2-dihydroindenderivater
JPH06184132A (ja)	1992-12-22	1994-07-05	Kotobuki Seiyaku Kk	ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤
ES2108484T3 (es)	1993-11-30	1997-12-16	Pfizer	Procedimiento para la preparacion de una tetralona asimetrica.
CA2132411A1 (en)	1994-09-19	1996-03-20	Michael Trani	Enzymatic esterification of long-chain racemic acids and alcohols
US6455736B1 (en)	1994-12-16	2002-09-24	Uop Llc	Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en)	1994-12-16	2002-06-25	Uop Llc	Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US5807897A (en)	1996-03-01	1998-09-15	Zeneca Limited	Aminotetralin derivative and compositions and method of use thereof
US6268367B1 (en)	1998-02-23	2001-07-31	Zymogenetics, Inc.	Piperazine derivatives for treating bone deficit conditions
ATE255555T1 (de)	1998-05-01	2003-12-15	Pfizer Prod Inc	Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
KR100605140B1 (ko)	1998-05-22	2006-07-28	싸이오스 인크	심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
DE19824470A1 (de)	1998-05-30	1999-12-02	Boehringer Ingelheim Pharma	Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9818916D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
FR2786769B1 (fr)	1998-12-04	2002-10-25	Synthelabo	Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1059302A1 (en)	1999-06-08	2000-12-13	Aventis Pharma Deutschland GmbH	Factor VIIa inhibitors
JP2000351773A (ja)	1999-06-08	2000-12-19	Yamanouchi Pharmaceut Co Ltd	フラン誘導体からなる医薬
AR031520A1 (es)	1999-06-11	2003-09-24	Vertex Pharma	Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US6369226B1 (en)	1999-06-21	2002-04-09	Agouron Pharmaceuticals, Inc.	Substituted benzamide inhibitors of rhinovirus 3C protease
IN187170B (sr)	2000-01-04	2002-02-23	Sun Pharmaceutical Ind Ltd
PL1658277T3 (pl) *	2003-08-18	2012-10-31	H Lundbeck As	Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
TWI453198B (zh)	2005-02-16	2014-09-21	Lundbeck & Co As H	製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
WO2006086985A1 (en)	2005-02-16	2006-08-24	H. Lundbeck A/S	Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TWI376373B (en)	2005-02-16	2012-11-11	Lundbeck & Co As H	Crystalline base of a pharmaceutical compound

2006
- 2006-02-07 TW TW095103995A patent/TWI376373B/zh not_active IP Right Cessation
- 2006-02-14 ES ES06706059T patent/ES2368786T3/es not_active Expired - Lifetime
- 2006-02-14 AR ARP060100519A patent/AR052909A1/es unknown
- 2006-02-14 WO PCT/DK2006/000088 patent/WO2006086986A1/en not_active Ceased
- 2006-02-14 DK DK06706059.0T patent/DK1853576T3/da active
- 2006-02-14 KR KR1020077017725A patent/KR101386387B1/ko not_active Expired - Fee Related
- 2006-02-14 HR HR20110645T patent/HRP20110645T1/hr unknown
- 2006-02-14 BR BRPI0607436A patent/BRPI0607436B8/pt not_active IP Right Cessation
- 2006-02-14 CN CN200680005006.1A patent/CN101119983B/zh not_active Expired - Fee Related
- 2006-02-14 SI SI200631104T patent/SI1853576T1/sl unknown
- 2006-02-14 AT AT06706059T patent/ATE515501T1/de active
- 2006-02-14 MX MX2007009980A patent/MX2007009980A/es active IP Right Grant
- 2006-02-14 JP JP2007554426A patent/JP5055135B2/ja not_active Expired - Fee Related
- 2006-02-14 RS RS20110418A patent/RS51944B/sr unknown
- 2006-02-14 UA UAA200710266A patent/UA95901C2/ru unknown
- 2006-02-14 CA CA2597622A patent/CA2597622C/en not_active Expired - Fee Related
- 2006-02-14 US US11/816,394 patent/US7648991B2/en not_active Expired - Fee Related
- 2006-02-14 NZ NZ556397A patent/NZ556397A/en not_active IP Right Cessation
- 2006-02-14 PL PL06706059T patent/PL1853576T3/pl unknown
- 2006-02-14 PT PT06706059T patent/PT1853576E/pt unknown
- 2006-02-14 ZA ZA200705982A patent/ZA200705982B/xx unknown
- 2006-02-14 EA EA200701740A patent/EA017631B1/ru unknown
- 2006-02-14 AU AU2006215957A patent/AU2006215957B9/en not_active Ceased
- 2006-02-14 EP EP06706059A patent/EP1853576B1/en not_active Expired - Lifetime
- 2006-02-15 MY MYPI20060624A patent/MY148683A/en unknown
2007
- 2007-07-12 IL IL184551A patent/IL184551A/en active IP Right Grant
- 2007-09-12 NO NO20074639A patent/NO339863B1/no not_active IP Right Cessation
2009
- 2009-12-01 US US12/628,613 patent/US8450324B2/en not_active Expired - Fee Related
2011
- 2011-09-27 CY CY20111100928T patent/CY1111857T1/el unknown

Also Published As

Publication number	Publication date
MY148683A (en)	2013-05-31
ZA200705982B (en)	2009-06-24
AU2006215957B2 (en)	2011-09-29
KR101386387B1 (ko)	2014-04-25
HK1117525A1 (en)	2009-01-16
CN101119983A (zh)	2008-02-06
SI1853576T1 (sl)	2011-11-30
US20080153848A1 (en)	2008-06-26
AR052909A1 (es)	2007-04-11
PL1853576T3 (pl)	2011-12-30
JP5055135B2 (ja)	2012-10-24
NO20074639L (no)	2007-09-12
BRPI0607436A2 (pt)	2010-04-06
AU2006215957B9 (en)	2012-02-16
EA200701740A1 (ru)	2007-12-28
EP1853576B1 (en)	2011-07-06
US20100105699A1 (en)	2010-04-29
EP1853576A1 (en)	2007-11-14
AU2006215957A1 (en)	2006-08-24
BRPI0607436B1 (pt)	2020-10-06
HRP20110645T1 (hr)	2011-10-31
CA2597622C (en)	2013-11-12
NZ556397A (en)	2010-06-25
KR20070103414A (ko)	2007-10-23
WO2006086986A1 (en)	2006-08-24
CN101119983B (zh)	2014-11-12
UA95901C2 (en)	2011-09-26
IL184551A0 (en)	2007-10-31
IL184551A (en)	2014-05-28
NO339863B1 (no)	2017-02-13
EA017631B1 (ru)	2013-02-28
ES2368786T3 (es)	2011-11-22
TW200640890A (en)	2006-12-01
ATE515501T1 (de)	2011-07-15
US8450324B2 (en)	2013-05-28
DK1853576T3 (da)	2011-09-26
PT1853576E (pt)	2011-09-28
TWI376373B (en)	2012-11-11
JP2008530040A (ja)	2008-08-07
BRPI0607436B8 (pt)	2021-05-25
RS51944B (sr)	2012-02-29
US7648991B2 (en)	2010-01-19
MX2007009980A (es)	2007-09-26
CA2597622A1 (en)	2006-08-24

Publication	Publication Date	Title
CY1111857T1 (el)	2015-11-04	Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης
CY1113039T1 (el)	2016-04-13	Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο
NO20056130L (no)	2006-02-27	Nye substituerte 3-svovelindoler
DK1519724T3 (da)	2010-01-04	Fredericamycin-derivater som lægemidler til behandling af tumorer
EA200500203A1 (ru)	2005-08-25	Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
SE0401971D0 (sv)	2004-08-02	Piperidne derivatives
CY1109998T1 (el)	2014-09-10	Ενδυναμωτες υποδοχεων γλουταμινικου
EA200800172A1 (ru)	2008-08-29	2,4-диаминопиримидины как ингибиторы aurora
EA200801565A1 (ru)	2008-12-30	Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
EA200901373A1 (ru)	2010-06-30	Аминогетероциклические соединения
CY1112653T1 (el)	2016-02-10	Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
UY28473A1 (es)	2005-03-31	Nuevos compuestos
UA87153C2 (ru)	2009-06-25	Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
CY1118179T1 (el)	2017-06-28	Φαρμακευτικη συνθεση
CY1108843T1 (el)	2014-07-02	3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
SE0300480D0 (sv)	2003-02-21	Novel compounds
SE0401970D0 (sv)	2004-08-02	Novel compounds
MY169274A (en)	2019-03-21	Fused, tricyclic sulfonamide inhibitors of gamma secretase
SE0302139D0 (sv)	2003-07-28	Novel compounds
SE0302546D0 (sv)	2003-09-24	New compounds
BRPI0417858A (pt)	2007-04-27	composto, composição farmacêutica, e, uso de uma composição farmacêutica
EA200701930A1 (ru)	2008-02-28	Производные пиримидина для лечения гиперпролиферативных нарушений
CY1109975T1 (el)	2014-09-10	Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
NO20054361D0 (no)	2005-09-20	Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
DE602006010738D1 (de)	2010-01-07	Pyrroloä2,3-cüpyridinderivate